{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T12:37:47Z","timestamp":1786451867873,"version":"build-2736575974"},"reference-count":40,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"unspecified","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008361","name":"Danish Multiple Sclerosis Society","doi-asserted-by":"crossref","award":["A45659"],"award-info":[{"award-number":["A45659"]}],"id":[{"id":"10.13039\/100008361","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Neurol Open"],"accepted":{"date-parts":[[2026,7,21]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The effect of early high-efficacy therapy initiation versus escalation from moderate-efficacy therapy on progression independent of relapse activity (PIRA) in multiple sclerosis remains unclear. This study aimed to compare the treatment strategies on effectiveness against PIRA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From the Danish MS Registry, treatment-na\u00efve adult patients with multiple sclerosis started on high-efficacy therapies or moderate-efficacy therapies between 2012 and 2022 were included in this nationwide cohort study. Stabilised inverse probability of treatment weights, derived from propensity scores, were applied to balance confounders and to perform weighted Cox and negative binomial regression models. Patients were followed under an intention-to-treat framework until the latest clinical visit before the data extraction date (2 June 2025). The primary outcome was time to first PIRA; the secondary outcome was annualised relapse rate (ARR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 3316 patients (594 high-efficacy, 2722 moderate-efficacy) with a median follow-up time of 7.4 years (min\u2013max: 1.5\u201313.4), we found no statistical difference in time to first progression independent of relapse activity with a HR of 0.89, 95% CI 0.59 to 1.36, p=0.60. Early high-efficacy therapy initiation was associated with a 40% reduction in ARR (incidence rate ratio of 0.60, 95%\u2009CI 0.46 to 0.77, p&lt;0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this nationwide cohort study, we found a reduction in relapse activity associated with early initiation of high-efficacy therapies but no statistically significant difference when investigating time to first PIRA. Our findings indicate a therapeutic gap in the current treatment landscape with respect to mitigating PIRA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjno-2026-001690","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T12:00:16Z","timestamp":1786449616000},"page":"e001690","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of escalation versus early high-efficacy therapies on progression independent of relapse activity in multiple sclerosis: a Danish nationwide study"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3431-194X","authenticated-orcid":false,"given":"Eliza","family":"Varju","sequence":"first","affiliation":[{"name":"The Danish Multiple Sclerosis Registry, Copenhagen University Hospital, Glostrup, Capital Region of Denmark, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Pontieri","sequence":"additional","affiliation":[{"name":"The Danish Multiple Sclerosis Registry, Copenhagen University Hospital, Glostrup, Capital Region of Denmark, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mie Reith","family":"Mahler","sequence":"additional","affiliation":[{"name":"The Danish Multiple Sclerosis Registry, Copenhagen University Hospital, Glostrup, Capital Region of Denmark, Denmark"},{"name":"Danish Multiple Sclerosis Center, Copenhagen University Hospital, Glostrup, Capital Region of Denmark, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0972-5222","authenticated-orcid":false,"given":"Melinda","family":"Magyari","sequence":"additional","affiliation":[{"name":"The Danish Multiple Sclerosis Registry, Copenhagen University Hospital, Glostrup, Capital Region of Denmark, Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"2026081105001005000_8.2.e001690.1","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12712"},{"key":"2026081105001005000_8.2.e001690.2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/acn3.180","article-title":"Comparative efficacy of switching to natalizumab in active multiple sclerosis","volume":"2","author":"Spelman","year":"2015","journal-title":"Ann Clin Transl Neurol"},{"key":"2026081105001005000_8.2.e001690.3","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s00415-018-9126-y","article-title":"Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy","volume":"266","author":"Chalmer","year":"2019","journal-title":"J Neurol"},{"key":"2026081105001005000_8.2.e001690.4","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010135"},{"key":"2026081105001005000_8.2.e001690.5","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.autrev.2017.04.010","article-title":"Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review","volume":"16","author":"Merkel","year":"2017","journal-title":"Autoimmun Rev"},{"key":"2026081105001005000_8.2.e001690.6","doi-asserted-by":"crossref","first-page":"105751","DOI":"10.1016\/j.msard.2024.105751","article-title":"Real-world evidence from Germany and the United States: Treatment initiation on low-efficacy versus high-efficacy therapies in patients with multiple sclerosis","volume":"88","author":"Papukchieva","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"2026081105001005000_8.2.e001690.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30067-3"},{"key":"2026081105001005000_8.2.e001690.8","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.3498","article-title":"Escalating to medium- versus high-efficacy disease modifying therapy after low-efficacy treatment in relapsing remitting multiple sclerosis","volume":"14","author":"M\u00fcller","year":"2024","journal-title":"Brain Behav"},{"key":"2026081105001005000_8.2.e001690.9","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1001\/jamaneurol.2018.4905","article-title":"Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis","volume":"76","author":"Harding","year":"2019","journal-title":"JAMA Neurol"},{"key":"2026081105001005000_8.2.e001690.10","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211019574","article-title":"Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies","volume":"14","author":"Iaffaldano","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"2026081105001005000_8.2.e001690.11","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26913"},{"key":"2026081105001005000_8.2.e001690.12","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac016"},{"key":"2026081105001005000_8.2.e001690.13","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/jamaneurol.2023.3331","article-title":"Harmonizing Definitions for Progression Independent of Relapse Activity in Multiple Sclerosis: A Systematic Review","volume":"80","author":"M\u00fcller","year":"2023","journal-title":"JAMA Neurol"},{"key":"2026081105001005000_8.2.e001690.14","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1001\/jamaneurol.2025.0495","article-title":"Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis","volume":"82","author":"M\u00fcller","year":"2025","journal-title":"JAMA Neurol"},{"key":"2026081105001005000_8.2.e001690.15","doi-asserted-by":"crossref","first-page":"103029","DOI":"10.1016\/j.msard.2021.103029","article-title":"Relapses add to permanent disability in relapsing multiple sclerosis patients","volume":"53","author":"Koch-Henriksen","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"2026081105001005000_8.2.e001690.16","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1177\/13524585241266180","article-title":"Disability patterns in multiple sclerosis: A meta-analysis on RAW and PIRA in the real-world context","volume":"30","author":"Prosperini","year":"2024","journal-title":"Mult Scler"},{"key":"2026081105001005000_8.2.e001690.17","doi-asserted-by":"crossref","first-page":"104899","DOI":"10.1016\/j.msard.2023.104899","article-title":"Defining progression independent of relapse activity (PIRA) in adult patients with relapsing multiple sclerosis: A systematic review\u2730","volume":"78","author":"Sharrad","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"2026081105001005000_8.2.e001690.18","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jamaneurol.2022.4655","article-title":"Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis","volume":"80","author":"Tur","year":"2023","journal-title":"JAMA Neurol"},{"key":"2026081105001005000_8.2.e001690.19","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials","volume":"77","author":"Kappos","year":"2020","journal-title":"JAMA Neurol"},{"key":"2026081105001005000_8.2.e001690.20","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1177\/13524585221078825","article-title":"Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II","volume":"28","author":"G\u00e4rtner","year":"2022","journal-title":"Mult Scler"},{"key":"2026081105001005000_8.2.e001690.21","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/1352458520918489","article-title":"Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta\/glatiramer acetate","volume":"27","author":"von Wyl","year":"2021","journal-title":"Mult Scler"},{"key":"2026081105001005000_8.2.e001690.22","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/acn3.70131","article-title":"Early Intensive Versus Escalation Approach: Ten-Year Impact on Disability in Relapsing Multiple Sclerosis","volume":"12","author":"Iaffaldano","year":"2025","journal-title":"Ann Clin Transl Neurol"},{"key":"2026081105001005000_8.2.e001690.23","unstructured":"Magyari M , Pontieri L , Joensen H . \u00c5rsrapport 2024. 2025."},{"key":"2026081105001005000_8.2.e001690.24","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1921","article-title":"The Danish Multiple Sclerosis Registry","volume":"11","author":"Magyari","year":"2021","journal-title":"Brain Behav"},{"key":"2026081105001005000_8.2.e001690.25","unstructured":"Medicinr\u00e5dets laegemiddelrekommandation vedr. laegemidler til attakvis multipel sklerose."},{"key":"2026081105001005000_8.2.e001690.26","first-page":"1","article-title":"Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial","volume":"78","author":"Cree","year":"2020","journal-title":"JAMA Neurol"},{"key":"2026081105001005000_8.2.e001690.27","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70099-0"},{"key":"2026081105001005000_8.2.e001690.28","doi-asserted-by":"crossref","first-page":"101376","DOI":"10.1016\/j.msard.2019.101376","article-title":"Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis","volume":"36","author":"Boz","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"2026081105001005000_8.2.e001690.29","doi-asserted-by":"crossref","unstructured":"Montobbio N , Carmisciano L , Signori A , et al . Creating an automated tool for a consistent and repeatable evaluation of disability progression in clinical studies for multiple sclerosis. Neurology [Preprint] 2024. doi:10.1101\/2024.01.30.24302013","DOI":"10.1101\/2024.01.30.24302013"},{"key":"2026081105001005000_8.2.e001690.30","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph18136694","article-title":"Propensity Score Analysis with Partially Observed Baseline Covariates: A Practical Comparison of Methods for Handling Missing Data","volume":"18","author":"Bottigliengo","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"2026081105001005000_8.2.e001690.31","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-200009000-00011"},{"key":"2026081105001005000_8.2.e001690.32","unstructured":"R Core Team . R: a language and environment for statistical computing."},{"key":"2026081105001005000_8.2.e001690.33","unstructured":"Therneau MT , Lumley T , Atkinson E , et al . Survival analysis."},{"key":"2026081105001005000_8.2.e001690.34","unstructured":"Greifer N . Cobalt: covariate balance tables and plots. R package version 4.6.1."},{"key":"2026081105001005000_8.2.e001690.35","doi-asserted-by":"publisher","DOI":"10.1002\/sim.9681"},{"key":"2026081105001005000_8.2.e001690.36","doi-asserted-by":"crossref","first-page":"106775","DOI":"10.1016\/j.msard.2025.106775","article-title":"Progression independent of relapse activity (PIRA) in the Era of high-efficacy treatments","volume":"104","author":"Alonso","year":"2025","journal-title":"Mult Scler Relat Disord"},{"key":"2026081105001005000_8.2.e001690.37","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517709619"},{"key":"2026081105001005000_8.2.e001690.38","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamaneurol.2021.2738","article-title":"Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies","volume":"78","author":"Spelman","year":"2021","journal-title":"JAMA Neurol"},{"key":"2026081105001005000_8.2.e001690.39","doi-asserted-by":"crossref","first-page":"104187","DOI":"10.1016\/j.msard.2022.104187","article-title":"Assessment of T2 lesion-based disease activity volume outcomes in predicting disease progression in multiple sclerosis over 10 years","volume":"67","author":"Oship","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"2026081105001005000_8.2.e001690.40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105802","article-title":"Uncovering a bias in estimated treatment effects on PIRA in multiple sclerosis clinical trials","volume":"117","author":"Montobbio","year":"2025","journal-title":"EBioMedicine"}],"container-title":["BMJ Neurology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjno-2026-001690","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T12:00:25Z","timestamp":1786449625000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurologyopen.bmj.com\/lookup\/doi\/10.1136\/bmjno-2026-001690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,8,11]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/bmjno-2026-001690"],"URL":"https:\/\/doi.org\/10.1136\/bmjno-2026-001690","relation":{},"ISSN":["2632-6140"],"issn-type":[{"value":"2632-6140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}